According to a recent survey, hereditary angioedema is a rare genetic disorder that affects approximately 1 in 50,000 people worldwide. It is characterized by recurrent episodes of swelling in the skin and mucous membranes, which can be painful and potentially life-threatening if they occur in the airways or digestive tract. The condition results from a deficiency or dysfunction of C1 inhibitor protein, which regulates immune system activity and prevents excess fluid from leaking out of blood vessels into surrounding tissues. Symptoms may first appear during childhood or adolescence and often worsen over time without proper treatment. There are currently several medications available to prevent attacks or treat acute symptoms, including plasma-derived C1 inhibitor replacement therapy, bradykinin receptor antagonists, and kallikrein inhibitors. However, many patients still struggle to obtain prompt diagnosis and access to these treatments due to limited awareness among healthcare providers and high costs associated with their use. Ongoing research efforts are focused on improving diagnostic accuracy, developing new therapies with longer duration of action or better tolerability profiles than existing options, and exploring potential links between hereditary angioedema and other inflammatory conditions such as autoimmune disease or cancer.
1.
Colon cancer and exercise: Can physical activity reprogram genes?
2.
For relapsed or resistant DLBCL, odronextamab produced positive results.
3.
Improved end-of-life conversations for cancer patients are identified by a new study.
4.
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
5.
Xerostomia in Head and Neck Cancer Patients Can Be Predicted by Mid-Treatment PET/CT Scans.
1.
Treating Methemoglobinemia: What You Need to Know Now!
2.
Is AI The New Radiologist For Breast MRI?
3.
Advancements in Squamous Cell Carcinoma Treatment: Decoding Survival Strategies and Molecular Pathways to Improve Cure Rates
4.
Unlocking the Potential of Pirtobrutinib: A New Frontier in Cancer Treatment
5.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
4.
Current Scenario of Cancer- An Overview of The Incidence of Cancer in Men
5.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation